Table 3.
Characteristics of Screened Patients by Anti-HCV Test Results
| Characteristic | Total Patients (n = 2,330) |
HCV Test Results |
P | ||||
|---|---|---|---|---|---|---|---|
| Positive (n = 35) |
Negative (n = 2,295) |
||||||
| No. | % | No. | % | No. | % | ||
| Age, years | .37 | ||||||
| Mean | 51.5 | 53.9 | 51.4 | ||||
| SD | 15.95 | 10.33 | 16.02 | ||||
| Birth year | < .01 | ||||||
| Before 1945 | 590 | 25.3 | 4 | 0.7 | 586 | 99.3 | |
| Between 1945 and 1965 | 1,071 | 46.0 | 26 | 2.4 | 1,045 | 97.6 | |
| After 1965* | 669 | 28.7 | 5 | 0.7 | 664 | 99.3 | |
| Sex | .24 | ||||||
| Male | 1,292 | 55.5 | 23 | 1.8 | 1,269 | 98.2 | |
| Female* | 1,038 | 44.5 | 12 | 1.2 | 1,026 | 98.8 | |
| Race/ethnicity | .21 | ||||||
| Hispanic | 336 | 14.4 | 1 | 0.3 | 335 | 99.7 | |
| Black | 225 | 9.7 | 5 | 2.2 | 220 | 97.8 | |
| Asian | 68 | 2.9 | 1 | 1.5 | 67 | 98.5 | |
| Other | 112 | 4.8 | 2 | 1.8 | 110 | 98.2 | |
| White* | 1,589 | 68.2 | 26 | 1.6 | 1,563 | 98.4 | |
| US residence | .40 | ||||||
| Yes | 2,225 | 95.5 | 35 | 1.6 | 2,190 | 98.4 | |
| No* | 105 | 4.5 | 0 | 0.0 | 105 | 100.0 | |
| Exposure-type risk factor† | .43 | ||||||
| Yes | 37 | 1.6 | 1 | 2.7 | 36 | 97.3 | |
| No* | 2,293 | 98.4 | 34 | 1.5 | 2,259 | 98.5 | |
| Other liver condition‡ | .59 | ||||||
| Yes | 270 | 11.6 | 5 | 1.9 | 265 | 98.1 | |
| No* | 2,060 | 88.4 | 30 | 1.5 | 2,030 | 98.5 | |
| ALT level§ | .46 | ||||||
| Elevated (≥ 57 IU/L) | 1,084 | 46.5 | 13 | 1.2 | 1,071 | 98.8 | |
| Unavailable | 17 | 0.7 | 0 | 0.0 | 17 | 100.0 | |
| Normal (< 57 IU/L) | 1,229 | 52.7 | 22 | 1.8 | 1,207 | 98.2 | |
| Cancer type | .32 | ||||||
| Breast | 105 | 4.5 | 3 | 2.9 | 102 | 97.1 | |
| Colorectal | 81 | 3.5 | 2 | 2.5 | 79 | 97.5 | |
| Lung | 40 | 1.7 | 1 | 2.5 | 39 | 97.5 | |
| Other solid tumor | 908 | 39.0 | 14 | 1.5 | 894 | 98.5 | |
| Hematologic malignancy* | 1,196 | 51.3 | 15 | 1.3 | 1,181 | 98.7 | |
| Rituximab therapy anticipated | > .99 | ||||||
| Yes | 409 | 17.6 | 6 | 1.5 | 403 | 98.5 | |
| No* | 1,921 | 82.4 | 29 | 1.5 | 1,892 | 98.5 | |
NOTE. Bold font indicates significance.
Abbreviations: anti-HCV, HCV antibody; HCV, hepatitis C virus; ICD-9, International Classification of Diseases (ninth edition); SD, standard deviation.
Reference group.
Exposure-type HCV risk factors included the following conditions and associated ICD-9 codes: HIV: 042, 079.53, V08, 795.71, V08; injection drug use: 305.90, 305.91, 305.92, 305.93; hemodialysis: 39.95; and hemophilia: V83.0, V83.01, V83.02, 286.52.
Other liver conditions included the following conditions and associated ICD-9 codes: 571, 571.1, 571.2, 571.3, 571.5, 571.6, 571.8, 571.9, 572, 572.2, 572.8, 782.4, 789.1.
All ALT measures observed from 60 days before beginning of screening period until end of screening period. Normal range of ALT at MD Anderson is 7 to 56 IU/L. Elevated ALT defined as ≥ one ALT value ≥ 57 IU/L.